We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Novartis has reached an agreement to buy Regulus Therapeutics and its experimental therapy for autosomal dominant polycystic kidney disease (ADPKD) for $800 million upfront in a deal that could ...

Regeneron to buy bankrupt 23andMe, vows ethical use of customer DNA data Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...

At close: May 20 at 4:00:00 PM EDT ...

As of 15:41:20 GMT-4. Market open.

ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, May 19, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene ...

CRISPR Therapeutics stock is down more than 80% from the peak it reached in 2021. The first drug from CRISPR Therapeutics launched early last year, but annualized sales are still less than $60 ...

The Company continues to work with Nuton to evaluate Nuton's proprietary sulphide bio-leaching technologies at the AntaKori project. The Phase One program identified that material from AntaKori was ...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. Monday - May 26 All ...

Retail giants Home Depot and Lowe's are set to report earnings this week. Euro area’s core CPI will be released on Monday, and UK’s on Wednesday. See more here.

Travere Therapeutics focuses on rare kidney and metabolic diseases, with strong revenue growth from recently approved Filspari and a narrowing loss in Q1 2024. Analysts generally remain bullish ...